MedTrace Logo

Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients

NCT03205150 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2021-10-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to assess the effects of LIK066 on a variety of metabolic and inflammation biomarkers in patients with non-alcoholic steatohepatitis (NASH)

Conditions

  • Obese Patients With Non-alcoholic Steatohepatitis (NASH)

Interventions

DRUG

LIK066

Film coated tablet of LIK066 either 30mg or 150 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84

DRUG

Placebo

LIK066 0 mg film-coated tablet(Placebo matching tablets) was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-04
Primary Completion
2019-11-11
Completion
2019-11-14
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Canada
  • Israel
  • Netherlands
  • Russia
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03205150 on ClinicalTrials.gov